InsidersTradesSigma
Track the Vir Biotechnology, Inc. share price and the full insider trade history of the company, a listed issuer based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Vir Biotechnology, Inc. has published 338 insider filings. Market capitalisation: €1.7bn. The latest transaction was disclosed on 21 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: SVF Endurance (Cayman) Ltd. All data is openly available.
338
Insider Decl.
n/a
Thresholds
€172,916
4 ops.
Buy Volume
€88m
145 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Vir Biotechnology, Inc. Strong Buy (bullish), based on 9 analysts. Average price target: US$21.00.
47Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 22,553 of 28,802 companies
31.9
score / 100
Value9
Quality55
FCF yld-24%
Earn yld-26%
EV/EBITDA·
ROE-26%
Gross mgn100%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 21 August 2026
Declarations338 total
25,000 shares@ US$9.8119CommonSEC144:0001959173-26-006329
8,000 shares0Common StockSEC:0001628280-26-056108:1
8,000 shares0Common StockSEC:0001628280-26-056108:0
16,000 shares@ US$10.32120.0100% mcap33.1% of flowCommonSEC144:0001959173-26-004947
8,000 sharesCommon StockSEC:0001628280-26-042326:0
8,000 sharesCommon StockSEC:0001628280-26-042326:1
8,000 shares0Common StockSEC:0001628280-26-038961:0
8,000 shares0Common StockSEC:0001628280-26-038962:0
22,000 shares@ US$10.04660.014% mcap2.1% of flowCommon StockSEC:0001628280-26-029640:0
233,532 shares0Common StockSEC:0001628280-26-029041:1
233,532 shares0Common StockSEC:0001628280-26-029041:0
72,559 shares@ US$9.15635.1% of flowCommon StockSEC:0001628280-26-024098:0
22,000 shares@ US$9.07350.013% mcap1.9% of flowCommon StockSEC:0001628280-26-022971:0
7,711 shares@ US$9.1281.6% of flowCommon StockSEC:0001628280-26-020823:0
2,500 shares0Common StockSEC:0001628280-26-020480:0
21,800 shares@ US$9.50391.7% of flowCommon StockSEC:0001628280-26-013630:0
1,616 shares@ US$9.53260.0010% mcap50.0% of flowCommon StockSEC:0001628280-26-012394:0
3,117 shares@ US$9.53260.0018% mcap50.0% of flowCommon StockSEC:0001628280-26-012393:0
42,377 shares@ US$1.4850.5% of flowCommon StockSEC:0001628280-26-012397:0
1,430 shares@ US$9.532612.0% of flowCommon StockSEC:0001628280-26-012396:0
1,634 shares@ US$9.532628.9% of flowCommon StockSEC:0001628280-26-012395:0
14,762 shares@ US$9.53266.8% of flowCommon StockSEC:0001628280-26-012390:0
25,000 shares0Common StockSEC:0001628280-26-011331:0
55,000 shares0Common StockSEC:0001628280-26-011330:0
55,000 shares0Common StockSEC:0001628280-26-011329:0
25 of 338 declarations
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is a United States-based biopharmaceutical company listed on the Nasdaq market in the United States, focused on discovering and developing therapies for serious infectious diseases, with a more recent expansion into selected oncology applications. Founded in 2016 and headquartered in San Francisco, California, the company was built around a technology-driven approach that combines antibodies, immunology, and protein-masking platforms to generate differentiated therapeutic candidates. ([stockanalysis.com](https://stockanalysis.com/stocks/vir/company/?utm_source=openai)) From a historical perspective, Vir Biotechnology initially established its identity around high-unmet-need viral diseases. Its portfolio has long included programs in hepatitis B, hepatitis delta, HIV, influenza, and COVID-19, spanning preclinical work through more advanced clinical stages. In its recent communications, the company has signaled a more selective and partnership-oriented strategy, while remaining open to out-licensing discussions for several programs, including hepatitis B, influenza, COVID-19, and HPV. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1706431/000162828024006852/vir-20231231.htm?utm_source=openai)) In competitive terms, Vir operates in a highly contested field populated by large pharmaceutical companies and numerous specialized biotech peers in immunology and infectious disease. Its competitive edge is centered on the scientific quality of its platform, the depth of its translational research, and its ability to structure partnerships with major industry players. The company has used licensing and collaboration agreements to support asset monetization while reducing the burden of funding the full pipeline on a standalone basis. ([investors.vir.bio](https://investors.vir.bio/news/news-details/2025/Vir-Biotechnology-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-EGFR-Targeting-PRO-XTEN-Dual-Masked-T-Cell-Engager-VIR-5525-for-the-Treatment-of-Solid-Tumors/default.aspx?utm_source=openai)) Among the most notable recent developments, Vir Biotechnology announced in 2025 first-in-human dosing of VIR-5525, a masked EGFR-targeting T-cell engager for solid tumors, highlighting a diversification beyond infectious diseases. The company also released its 2025 full-year results in 2026, underscoring active capital management and continued clinical progress. For French-speaking investors, the key question remains whether Vir can convert a scientifically promising platform into durable clinical, and eventually commercial, value creation in a highly selective Nasdaq biotech environment. ([investors.vir.bio](https://investors.vir.bio/news/news-details/2025/Vir-Biotechnology-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-EGFR-Targeting-PRO-XTEN-Dual-Masked-T-Cell-Engager-VIR-5525-for-the-Treatment-of-Solid-Tumors/default.aspx?utm_source=openai))
